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Probiotics can modulate gut microbiota, intestinal permeability, and immune response and could therefore improve 
cognitive dysfunction and help avoid potential consequences, such as falls, in patients with cirrhosis. The aim of this 
study was to evaluate the effect of a multistrain probiotic on cognitive function, risk of falls, and inf lammatory re-
sponse in patients with cirrhosis. Consecutive outpatients with cirrhosis and cognitive dysfunction (defined by a 
Psychometric Hepatic Encephalopathy Score [PHES] < −4) and/or falls in the previous year were randomized to 
receive either a sachet of a high-concentration multistrain probiotic containing 450 billion bacteria twice daily for 12 
weeks or placebo. We evaluated the changes in cognitive function (PHES); risk of falls (Timed Up and Go [TUG] 
test, gait speed, and incidence of falls); systemic inf lammatory response; neutrophil oxidative burst; intestinal barrier 
integrity (serum fatty acid–binding protein 6 [FABP-6] and 2 [FABP-2] and zonulin and urinary claudin-3); bacte-
rial translocation (lipopolysaccharide-binding protein [LBP]); and fecal microbiota. Thirty-six patients were included. 
Patients treated with the probiotic (n = 18) showed an improvement in the PHES (P = 0.006), TUG time (P = 
0.015) and gait speed (P = 0.02), and a trend toward a lower incidence of falls during follow-up (0% compared with 
22.2% in the placebo group [n = 18]; P = 0.10). In the probiotic group, we observed a decrease in C-reactive protein 
(P = 0.01), tumor necrosis factor alpha (P = 0.01), FABP-6 (P = 0.009), and claudin-3 (P = 0.002), and an increase 
in poststimulation neutrophil oxidative burst (P = 0.002). Conclusion: The multistrain probiotic improved cognitive 
function, risk of falls, and inf lammatory response in patients with cirrhosis and cognitive dysfunction and/or previ-
ous falls. (Hepatology Communications 2019;3:632-645).
Intestinal dysbiosis, gut barrier failure, bacte-rial translocation, and subsequent inflammatory response are key factors in the progression of liver diseases.(1) These factors have also been implicated in worsening of liver failure and portal hypertension and, consequently, in the development of complications, 
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12-myristate 13-acetate; TUG, Timed Up and Go test.
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including cognitive dysfunction, after advanced 
chronic liver disease or cirrhosis is established.(1-3)
Cognitive dysfunction, or minimal hepatic enceph-
alopathy, is a risk factor for overt hepatic encepha-
lopathy, worsening in health-related quality of life 
(HRQOL), traffic accidents, and mortality in patients 
with cirrhosis.(4-6) In addition, these patients are more 
predisposed to accidental falls.(7,8)
Falls are particularly important in patients with cir-
rhosis, because they have a greater risk of fracture than 
the general population.(9) Moreover, falls are a signif-
icant cause of complications, mortality, and HRQOL 
impairment.(6-9) In addition to their negative conse-
quences for the patient, falls have implications for the 
patient’s relatives and are an economic and social bur-
den for the community.(10) Moreover, individuals with 
previous falls are frequently predisposed to recurrent 
falling,(7,8,11) thus supporting the growing concept of 
frailty in patients with cirrhosis(12) and the need for 
preventive measures.(7-9)
Probiotics can modulate gut microbiota, the intes-
tinal barrier, and the immune response and could 
therefore decrease pathological bacterial translocation 
and ameliorate immune system alterations in cirrho-
sis.(1,13-15) These changes could not only improve liver 
function and help prevent bacterial infections and 
other complications, but also ameliorate cognitive 
dysfunction and avoid its consequences, such as overt 
hepatic encephalopathy, traffic accidents, deterioration 
of HRQOL, and falls.(1,13,14)
Studies have shown that certain probiotics improve 
the proinflammatory state,(1,13,15) liver function,(1) 
portal hemodynamics,(1) cognitive function,(1,16) 
incidence of overt hepatic encephalopathy,(1,16) and 
HRQOL(1) in patients with cirrhosis. However, the 
effect of probiotics on the risk of falling in these 
patients has not been previously evaluated.
The aim of this study was to evaluate the effect of 
a multistrain probiotic on cognitive function and the 
risk of falls in patients with cirrhosis who also have 
cognitive dysfunction and/or previous falls. We also 
studied potential mediators of these effects, particu-
larly the systemic inflammatory response, the gut bar-
rier, bacterial translocation, and intestinal microbiota.
Patients and Methods
Between February 2013 and March 2016, we per-
formed a double-blind placebo-controlled randomized 
trial at Hospital de la Santa Creu i Sant Pau, a ter-
tiary care hospital in Barcelona, Spain. The protocol 
conformed to the 1975 Declaration of Helsinki and 
Guidelines for Good Clinical Practice in Clinical Trials 
and was approved by the clinical research ethics com-
mittee (Comitè d’Ètica d’Investigació Clínica-CEIC) 
at our institution. Monitoring was performed by the 
Research Institute (IIB-Sant Pau) according to good 
clinical practice recommendations. All patients received 
information regarding their participation in the study 
and signed an informed consent form. The protocol 
was registered at ClinicalTrials.gov (NCT01686698).
patient seleCtion
We included consecutive outpatients with cirrhosis 
who had cognitive dysfunction and/or falls during the 
previous year and were visited at the nursing outpa-
tient office. Patients were selected by the nurses and 
hepatologists involved in the study. Cirrhosis was 
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diagnosed by means of clinical, analytical, and ultraso-
nographic findings or by liver biopsy. The presence of 
cognitive dysfunction was defined as a Psychometric 
Hepatic Encephalopathy Score (PHES) of less than 
−4,(17,18) and previous falls were assessed using a 
described questionnaire.(7,8) Exclusion criteria were 
hospitalization during the previous month, hepato-
cellular carcinoma or any other neoplasia, acute or 
chronic overt hepatic encephalopathy, neurologic dis-
ease, active alcohol intake (in the previous 3 months), 
clinically significant cognitive impairment, inability to 
perform psychometric tests, severe comorbidities, life 
expectancy of less than 6 months, any treatment with 
nonabsorbable disaccharides, laxatives, antibiotics 
and/or antivirals in the previous 3 months, and refusal 
to participate in the study.
stuDy Design
Patients were randomized by a hepatologist, other 
than those who selected the patients, to take either 
a probiotic (probiotic group) or a placebo (placebo 
group). Randomization was performed by means of 
a computer-generated sequence using blocks of four 
and consecutively numbered opaque sealed envelopes. 
All patients were treated for 12 weeks and assessed at 
baseline and at 12 weeks (end of treatment) for clini-
cal and analytical data, complications of cirrhosis, side 
effects, adherence, cognitive function, risk of falls, sys-
temic inflammatory response, and biomarkers of intes-
tinal barrier and bacterial translocation. A subgroup of 
patients was evaluated for fecal microbiota. Additional 
visits were performed at week 6 and week 20 (8 weeks 
after the end of treatment) to check patients’ clinical 
and analytical (routine standard analysis) status, side 
effects, adherence (only at week 6), and incidence of 
falls. Patients were instructed to return the boxes with 
the used and unused sachets at the week 6 and week 
12 visits to assess the adherence. The blinding was 
maintained for participants and the study team until 
the end of the study and the analysis of the results.
stuDy pRoDuCt
The probiotic formulation was a mixture of eight 
strains, namely, Streptococcus thermophilus DSM 
24731, Bifidobacterium breve (B. breve) DSM 24732, 
B. longum DSM 24736, B. infantis DSM 24737, 
Lactobacillus paracasei (L. paracasei) DSM 24733, 
L. acidophilus DSM 24735, L. delbrueckii subsp bul-
garicus DSM 24734, and L. plantarum DSM 24730, 
at a total dose of 450 billion live bacteria per 4.4 g 
sachet with maltose and silicon dioxide as excipients. 
The probiotic mixture was manufactured by Danisco-
DuPont (Madison, WI) and is currently marketed 
under the brand Vivomixx (MENDES, S.A., Lugano, 
Switzerland) in Europe and Visbiome (ExeGi 
Pharmaceuticals, Rockville, MD) in the United 
States. The placebo contained maltose and silicon 
dioxide as inactive agents and was formulated as iden-
tical in appearance to the active agent. Patients were 
instructed to keep the study product at 4ºC in the 
refrigerator at home and to take one sachet diluted in 
one glass of water, milk, or juice at room temperature 
twice daily (every 12 hours) over 12 weeks.
outComes anD enDpoints
At baseline and at the end of treatment, we assessed 
cognitive function according to PHES and the risk of 
falls by means of the Timed Up and Go (TUG) test 
and gait speed. The main endpoints were cognitive 
function and risk of falls, and the secondary endpoints 
were fall incidence, HRQOL, systemic inflammatory 
response, gut barrier, bacterial translocation, and fecal 
microbiota.
CliniCal anD analytiCal 
Data
At baseline, week 6, week 12 (end of treatment), 
and week 20 (end of study), we recorded demographic, 
clinical, and analytical data. We also recorded param-
eters that can influence the predisposition to fall, 
including comorbidity, muscular strength, visual acuity 
assessed by the Snellen test, and walking problems.(7,8)
CognitiVe FunCtion
Cognitive function was evaluated by the PHES, 
a neuropsychological battery widely used to assess 
cognitive function in patients with cirrhosis,(17) vali-
dated for the Spanish population,(18) using the com-
puter program of the Spanish Network of Hepatic 
Encephalopathy (www.redeh.org). Patients were con-
sidered to show minimal hepatic encephalopathy or 
cognitive dysfunction when they showed a PHES 
score of less than −4.(17,18)
Hepatology CommuniCations, Vol. 3, no. 5, 2019 ROMÁN, NIETO, ET AL.
635
RisK oF Falls
The risk of falling was assessed using the TUG 
test and gait speed.(8,19,20) The TUG test measures 
the time the patient needs to stand up from a chair, 
walk 3 m, turn around, walk back, and sit down in 
the chair without support. Gait speed was measured 
according to the time taken to walk 5 m. Gait speed 
is generally considered as abnormal and representative 
of increased risk of falling when it is 1 m/second or 
slower.(19)
inCiDenCe oF Falls
Falls were prospectively assessed at each visit 
during the study using a described specific question-
naire(7,8) and a revision of clinical records. The num-
ber of falls, severity of injuries, and health care needed 
were also recorded. Injuries were categorized as con-
tusion, wound or fracture, and health care needed was 
classified as primary care, emergency room care, or 
hospitalization.(7,8)
HanD gRip musCulaR 
stRengtH
Sarcopenia, a factor related to the predisposition to 
fall,(11) was evaluated by hand grip muscular strength 
using a dynamometer (KERN MAP-BA-s-0910) fol-
lowing the manufacturer’s instructions.
HRQol
To evaluate HRQOL, we used the Nottingham 
Health Profile (NHP), a general questionnaire that 
has been used in patients with cirrhosis.(21) The NHP 
has two parts. The first part includes 38 items that 
cover six domains, with scores ranging from 0 to 100. 
The second part consists of seven questions about 
limitations due to health problems in relation to seven 
functional activities of daily life: occupation, house-
work, social life, family life, sexual function, hobbies, 
and holidays. Higher scores or percentages indicate 
worse quality of life. We used the validated Spanish 
version of the NHP.(22)
systemiC inFlammation
We determined serum C-reactive protein (CRP), 
tumor necrosis factor alpha (TNF-α), interleukin 
(IL) 10 (BD Pharmingen, San Diego, CA), and 
IL-6 (ImmunoTools, Friesoythe, Germany) in serum 
using specific enzyme-linked immunosorbent assays 
(ELISA). To determine neutrophil oxidative burst 
(reactive oxidants), we incubated 105 peripheral blood 
cells for 20 minutes either with 200 ng/mL phorbol 
12-myristate 13-acetate (PMA) (Sigma-Aldrich, St. 
Louis, MO) or without stimulus at 37ºC. The forma-
tion of reactive oxidants was monitored by the oxi-
dation of dihydrorhodamine 123 (Sigma-Aldrich) to 
rhodamine by flow cytometry.
intestinal BaRRieR anD 
BaCteRial tRansloCation
The integrity of the intestinal barrier was assessed 
indirectly by the determination of fatty acid–binding 
protein 6 (FABP-6; Cloud-Clone Corp., Houston, 
TX), FABP-2 (Cloud-Clone Corp.), and zonulin 
(Bioss Antibodies Inc., Woburn, MA) in serum, and 
claudin-3 in urine (Elabscience, Houston, TX)(23,24) 
using specific ELISA. We determined lipopoly-
saccharide-binding protein (LBP) concentration 
in serum using specific ELISA (Biometec GmbH, 
Greifswald, Germany) according to the manufactur-
er’s instructions.
FeCal miCRoBiome analysis
We analyzed the fecal microbiome in the second 
half of patients included in the study. Patients pro-
vided fecal samples at baseline and at 12 weeks (end 
of treatment) to assess changes in their microbiomes. 
The methods for sample collection, genomic DNA 
extraction, and high-throughput DNA sequenc-
ing have been described(25) and are detailed in the 
Supporting Information.
statistiCal analysis
To compare the two groups at baseline, we used 
the Fisher’s exact test for categorical variables. The 
Student t test (if the data distribution was normal) 
or the Mann-Whitney U test (if the distribution was 
not normal) were used for quantitative variables. To 
compare the changes between baseline and the end of 
treatment in each group, we used the Student t test if 
the data distribution was normal and the Wilcoxon 
test if the distribution was not normal. Normality was 
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assessed by the Shapiro–Wilk test. Correlations were 
assessed by the Spearman test. Data are expressed 
as frequencies, percentages, and mean ± SEM. A 
two-sided P value of less than 0.05 was considered 
statistically significant. The methods used for statis-
tical analysis of changes in the fecal microbiome are 
described in the Supporting Information.
Sample size was calculated according to previous 
data on the effect of the probiotic on cognitive func-
tion in patients with cirrhosis.(16) We used the com-
puter program GRANMO version 7.12, released in 
2012 and developed by the Institut Municipal d’In-
vestigació Mèdica, Barcelona, Spain. We considered a 
resolution rate of minimal hepatic encephalopathy of 
55% in patients receiving the probiotic versus 10% in 
patients receiving placebo. With a calculated 10% of 
patients lost during follow-up, an alpha error of 0.05, 
and a power of 0.80, 17 patients per group would be 
necessary to show statistically significant differences 
in the effect on cognitive function between the pro-
biotic and the placebo. Statistical analysis was per-
formed using the program released in 2017 (IBM 
SPSS Statistics for Windows, Version 25.0; IBM 
Corp, Armonk, NY).
Results
patient CHaRaCteRistiCs
From February 2013 to March 2016, 279 patients 
with cirrhosis were evaluated for eligibility at the 
nursing outpatient office (Fig. 1). Of the patients, 158 
had a PHES of at least −4 and no previous falls, and 
therefore did not fulfill the inclusion criteria. Of the 
remaining 121 patients, 85 met one or more exclusion 
criteria. Finally, 36 patients were randomized to one 
of two groups: 18 to the probiotic group and 18 to 
the placebo group. As indicated in Table 1, the two 
groups had similar clinical and analytical characteris-
tics at baseline. In the probiotic group, 1 patient died 
during the treatment period and therefore was not 
evaluated at the 12-week visit (end of treatment), and 
we could not determine gait speed and TUG test at 
the end of treatment in another patient due to hip 
enthesitis. In the placebo group, 1 patient died after 
the end of treatment but before the 20-week fol-
low-up visit.
CognitiVe FunCtion
Cognitive function evaluated by the PHES 
improved at the end of treatment (12-week visit) 
compared with baseline results in the probiotic group 
(−1.29 ± 0.72 to −0.35 ± 0.82; P = 0.006). No changes 
were observed in patients in the placebo group 
(Fig. 2).
RisK oF Falling anD 
inCiDenCe oF Falls
We observed a decrease in TUG (11.38 ± 0.57 to 
10.00 ± 0.49 seconds; P = 0.015) and an increase 
in gait speed (0.90 ± 0.05 to 1.12 ± 0.10 m/second; 
P = 0.02) at the end of treatment (12-week visit) in 
comparison to the baseline results in the probiotic 
group, whereas we did not observe changes in the 
placebo group (Fig. 2).
The incidence of falls throughout the 20 weeks 
of the study was 0 of 18 (0%) in the probiotic group 
and 4 of 18 (22.2%) in the placebo group (P = 0.10). 
Regarding the severity of injuries due to falls, one fall 
caused a wound, whereas the others involved contu-
sions only. The patients were treated at primary health 
care centers, and one was seen at the emergency room. 
No hospitalizations were required.
HanD gRip musCulaR 
stRengtH
No statistically significant differences were found 
between baseline and end-of-treatment results either 
in the probiotic group (20.76 ± 2.27 to 20.62 ± 2.05 kg; 
P = 0.78) or in the placebo group (20.98 ± 2.28 to 
20.24 ± 2.05 kg; P = 0.12).
HRQol
At baseline, patients in both groups showed a rea-
sonably well-preserved HRQOL, as seen from the low 
values in each domain from the first part of the NHP 
and in the functional activities of daily life in the sec-
ond part of the questionnaire (Supporting Fig. S1). 
We did not observe statistically significant changes at 
the end of the treatment in either group, but there was 
a trend to an improvement in the domain of social 
isolation in the probiotic group (P = 0.05).
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liVeR anD Renal FunCtion
As indicated in Table 2, no variations in liver or 
renal function were found at the end of treatment in 
comparison to baseline values in either group.
systemiC inFlammatoRy 
Response
There was a decrease in serum CRP (7.62 ± 2.64 
to 3.45 ± 0.98 mg/L; P = 0.01) and TNF-α (P = 0.01) 
at the end of treatment in the probiotic group, with-
out significant changes in IL-6 or IL-10. Neutrophil 
oxidative burst after stimulation with PMA increased 
significantly at the end of treatment in the probiotic 
group (P = 0.002), without significant changes in rest-
ing oxidative burst. No changes were observed in the 
placebo group (Fig. 3).
intestinal BaRRieR anD 
BaCteRial tRansloCation
Regarding the intestinal barrier, there was a 
decrease in serum FABP-6 (P = 0.009) and urinary 
claudin-3 (P = 0.002) in the probiotic group at the 
end of treatment without changes in serum FABP-2 
or zonulin. There were no variations in the placebo 
group. We observed a not statistically significant trend 
toward a decrease in LBP in the probiotic group 
(P = 0.13) (Fig. 4).
Fig. 1. Flowchart of the study. After the end of treatment (week 12), patients were followed up until week 20. One patient in the 
placebo group died during this period, at week 16.
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FeCal miCRoBiota
We analyzed the changes in the fecal microbiota 
in the second half of patients included in the study 
(9 patients from the probiotic group and 8 patients 
from the placebo group). We did not observe signifi-
cant changes at the end of the treatment in compar-
ison with baseline data in either group at a phylum, 
genus, or species level (false discovery rates > 0.21 
for all phylogenetic levels and all bacterial groups). 
Sequence data were deposited in the National Center 
for Biotechnology Information database, with access 
number PRJNA499079.
CoRRelations among 
intestinal BaRRieR, 
inFlammatoRy Response, 
CognitiVe FunCtion, anD 
RisK oF Falling
Including all patients from the two groups at base-
line, we observed mild but significant correlations 
between FABP-6 and LBP (r = 0.54; P = 0.002); 
FABP-6 and CRP (r = 0.40; P = 0.01); LBP and 
CRP (r = 0.42; P = 0.01); CRP and poststimulated 
neutrophil oxidative burst (r = −0.43; P = 0.01); post-
stimulated oxidative burst and TUG test (r = −0.37; 
P = 0.03); and TUG test and PHES score (r = −0.41; 
P = 0.01).
aDVeRse eVents, 
CompliCations oF CiRRHosis, 
anD moRtality
The incidence and number of adverse events and 
severe adverse events during treatment and follow-up 
were similar in the two groups (Supporting Table 
S1). Ten patients (55.5%) in the probiotic group and 
12 patients (66.6%) in the placebo group (P = 0.73) 
presented 13 and 21 adverse events, respectively. 
Specifically, in the probiotic group, 2 patients pre-
sented complications of cirrhosis (1 patient died at 
week 6 due to respiratory infection and spontaneous 
bacterial peritonitis [SBP], and another presented 
grade 2 hepatic encephalopathy). In the placebo 
group, 3 patients presented complications of cirrhosis 
(1 patient was diagnosed with hepatocellular carci-
noma, 1 patient developed ascites, and another died 
at week 16 due to SBP). Overall mortality during the 
study was therefore 2 of 36 (5.5%), 1 patient in each 
group. Regarding infections, 4 patients from the pro-
biotic group presented five infections, and 5 patients 
from the placebo group presented five infections 
(Supporting Table S1). No adverse events attributable 
to the study product were observed. Overall adherence 
was considered satisfactory, as patients took 95.8% of 
the assigned sachets (97.2% in the probiotic group 
and 94.4% in the placebo group).
taBle 1. Baseline CliniCal anD analytiCal 
CHaRaCteRistiCs oF patients FRom tHe 
plaCeBo anD pRoBiotiC gRoups
Placebo 
Group  
(n = 18)
Probiotic 
Group  
(n = 18) P
Age (years) 64.0 ± 2.6 65.8 ± 3.1 0.65
Sex (male/female) 8 (44.4)/10 
(55.6)
6 (33.3)/12 
(66.7)
0.73
Etiology (%) 0.90
Alcohol 10 (55.6) 9 (50)
Hepatitis C virus 3 (16.7) 3 (16.7)
Hepatitis B virus 1 (5.6) 1 (5.6)
Hepatitis C virus and alcohol 2 (11.1) 1 (5.6)
Other 2 (11.1) 4 (22.2)
Previous decompensations (%) 13 (72.2) 16 (88.9) 0.40
Previous hepatocellular carcinoma (%) 2 (11.1) 1 (5.6) 1.00
Child-Pugh score 6.0 ± 0.4 5.9 ± 0.2 0.42
MELD score 9.3 ± 0.8 9.0 ± 0.9 0.78
Minimal hepatic encephalopathy (%) 6 (33.3) 4 (22.2) 0.71
Previous falls (%) 15 (83.3) 15 (83.3) 1.00
Severe deficit visual acuity* (%) 0 0 1.00
Walking problems† (%) 4 (22.2) 2 (11.1) 0.66
Modified Charlson comorbidity score 2.8 ± 0.3 2.5 ± 0.4 0.46
Body mass index (kg/m2) 28.9 ± 1.7 26.1 ± 0.9 0.27
Diabetes mellitus (%) 6 (33.3) 5 (27.8) 1.00
Diuretics (%) 10 (55.6) 11 (61.1) 1.00
Beta blockers (%) 7 (38.9) 8 (44.4) 1.00
Proton pump inhibitors (%) 10 (55.6) 9 (50) 1.00
Antidepressants (%) 2 (11.1) 2 (11.1) 1.00
Serum sodium (mmol/L) 138.7 ± 0.8 140.1 ± 0.8 0.35
Serum creatinine (µmol/L) 76.1 ± 6.2 80.5 ± 8.1 0.67
Serum bilirubin (µmol/L) 21.1 ± 4.6 19.2 ± 2.6 0.88
Serum albumin (g/L) 36.8 ± 1.4 37.7 ± 0.8 0.49
INR 1.18 ± 0.04 1.19 ± 0.06 0.44
Mean arterial pressure (mm Hg)‡ 91.3 ± 3.4 94.7 ± 4.3 0.54
Note: Data are expressed as number (%) of patients and mean ± 
standard error of the mean.
*Less than 3 of 10 using Snellen number chart.
†Use of any walking-aid device.
‡Millimeters of mercury.
Abbreviations: INR, international normalized ratio; and MELD, 
Model for End-Stage Liver Disease.
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Discussion
The main finding of the present study is that treat-
ment with a multistrain probiotic improved cognitive 
function and decreased the risk of falling in patients 
with cirrhosis who had cognitive dysfunction and/or 
previous falls.
Because of the strict exclusion criteria to avoid 
confounding factors, the patients included were highly 
selected and in a stable clinical situation, as can be 
observed by their low Child-Pugh and Model for End-
Stage Liver Disease scores and the low prevalence of 
abnormal PHES results. Most of them were included 
in the study because of previous falls, and their TUG 
test and gait speed values were clearly impaired and 
indicative of risk of falling.(19,20) At the end of the 
probiotic treatment, however, the final results of the 
TUG test and gait speed indicated an improvement 
in the risk of falls in the probiotic group, but not in 
the placebo group.(19,20) Moreover, there was a not 
significant decrease in the incidence of accidental falls 
throughout the study in patients from the probiotic 
group in comparison with the placebo group (0% ver-
sus 22.2%), although the study was not designed with 
the statistical power to demonstrate differences in this 
clinical endpoint.
The cause of the predisposition of patients with 
cirrhosis to falling is probably multifactorial, but cog-
nitive dysfunction (or minimal hepatic encephalopa-
thy) appears to play an important role.(8,26) Cognitive 
function improved in patients from the probiotic 
group, as shown by the increase in the PHES results 
Fig. 2. Cognitive function assessed by the PHES (A) and risk of falls assessed by TUG test (B) and gait speed (C) at baseline and at 
the end of treatment (12 weeks) in the placebo group (n = 18) and in the probiotic group (n = 17 for PHES and n = 16 for TUG and gait 
speed). Data are expressed as mean ± SEM. P is not significant for any parameters in the placebo group.
taBle 2. liVeR anD Renal FunCtion at Baseline anD at tHe enD oF tReatment (WeeK 12) in 
tHe plaCeBo gRoup anD tHe pRoBiotiC gRoup
Placebo Group (n = 18) Probiotic Group (n = 17)
Baseline
End of Treatment 
(week 12) P Baseline
End of Treatment 
(week 12) P
Serum sodium (mmol/L) 138.7 ± 0.8 139.2 ± 0.7 0.47 139.7 ± 0.8 139.9 ± 0.8 0.84
Serum creatinine (µmol/L) 76.1 ± 6.2 75.3 ± 6.6 0.69 74.0 ± 5.2 75.0 ± 6.7 0.66
Serum bilirubin (µmol/L) 21.1 ± 4.6 23.2 ± 5.3 0.10 18.2 ± 2.6 18.6 ± 2.5 1.00
Serum albumin (g/L) 36.8 ± 1.4 37.3 ± 1.3 0.23 37.9 ± 0.8 38.1 ± 0.7 0.54
INR 1.18 ± 0.04 1.19 ± 0.04 0.58 1.20 ± 0.06 1.15 ± 0.05 0.69
AST (U/L) 43.5 ± 4.7 46.1 ± 4.9 0.43 38.6 ± 5.7 36.9 ± 5.4 0.80
ALT (U/L) 36.4 ± 5.1 41.3 ± 6.5 0.76 30.7 ± 8.1 36.3 ± 9.3 0.06
GGT (U/L) 92.7 ± 16.1 110.0 ± 22.2 0.34 68.4 ± 15.4 55.2 ± 10.4 0.05
Note: Data are expressed as mean ± SEM.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; and INR, inter-
national normalized ratio.
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at the end of the treatment. This finding is in agree-
ment with studies reporting an improvement in cog-
nitive function in patients with cirrhosis treated with 
the probiotic used here(16,27) as well as in studies using 
other probiotics.(1,13,28)
Most patients in our study had a baseline PHES 
of at least −4, which is above the limit to diagnose 
minimal hepatic encephalopathy. Therefore, we could 
be skeptical about the clinical significance of the 
improvement in the PHES observed in the probiotic 
group. However, Giménez-Garzó et al.(29) recently 
demonstrated that patients with a normal PHES may 
exhibit different types of neuropsychological alter-
ations that are mild but have clinical consequences. 
These data are in line with previous studies showing a 
lack of correlation between the incidence of falls and 
the degree of impairment in the PHES.(8) In addition, 
the alterations in brain white matter tracts observed 
by magnetic resonance–diffusion tensor imaging in 
patients with cirrhosis and previous falls were not 
related to the PHES results, but to more accurate 
tests of executive function, such as the Wisconsin 
Card Sorting Test.(30) According to these data, 
impaired PHES could be a surrogate marker of the 
underlying brain alterations that predispose patients 
with cirrhosis to falling.(30) We consider that the 
improvement in the PHES observed in our study in 
patients treated with the probiotics may have clinical 
relevance, especially considering that it was associated 
with an improvement in the tests to assess the risk of 
falls. Recently, Pinto-Sanchez et al.(31) reported that 
treatment with the probiotic B. longum NCC3001 
in patients with irritable bowel syndrome produced 
changes in the cerebral activation pattern evaluated 
by functional magnetic resonance imaging (MRI). It 
would be interesting to use this technique to study 
the effect of probiotics on brain function in patients 
with cirrhosis.
The lack of statistically significant improvements 
in HRQOL measured by the NHP could be due to 
Fig. 3. Parameters of systemic inf lammatory response at baseline and at the end of treatment (12 weeks) in the placebo group and in 
the probiotic group: CRP (A), TNF-α (B), neutrophil resting oxidative burst (C), IL-6 (D), IL-10 (E), and neutrophil oxidative burst 
after PMA stimulation (F). Data are expressed as mean ± SEM. P is not significant for any parameters in the placebo group and for 
IL-6, IL-10, and neutrophil resting oxidative burst in the probiotic group. Abbreviations: MFI, mean f luorescence intensity; Rho, 
rhodamine.
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the fact that patients presented a relatively well-pre-
served baseline HRQOL that was therefore difficult 
to ameliorate. Another possible explanation is that 
the improvements in physical and cognitive func-
tions were insufficient to improve the multifactorial 
HRQOL in patients with cirrhosis. Nevertheless, we 
observed a not significant trend to improvement in 
the domain of social isolation in the probiotic group.
We aimed to explore the potential mechanisms 
by which the probiotic may have improved cogni-
tive function and decreased the risk of falling, such 
as modulation of systemic inflammation, improve-
ment of the intestinal barrier, and changes in bacterial 
translocation and gut microbiota.(1,3,13,14)
Regarding systemic inflammation, baseline serum 
CRP levels were slightly increased in the two groups, 
suggesting a mild proinflammatory state, as may 
have been expected considering the characteristics 
of the patients included in the study. However, only 
patients in the probiotic group presented a decrease 
in CRP levels to almost normal values at the end of 
the treatment, and this was associated with a signifi-
cant decrease in serum TNF-α. Taking into consid-
eration the importance of a proinflammatory state, 
and CRP in particular, in the prognosis of patients 
with cirrhosis,(2,32) we consider this one of the most 
relevant findings in our study. Specifically, systemic 
inflammation is related to neuroinflammation, which 
in turn is a main factor involved in the pathophysi-
ology of covert and overt hepatic encephalopathy.(1-3) 
In common bile duct ligated mice, D’Mello et al.(33) 
showed that treatment with the same probiotic mix-
ture as that used here reduced systemic inflammation, 
improved activation of brain microglia and cere-
bral monocyte infiltration, and ameliorated sickness 
behavior. In patients with cirrhosis treated with the 
same probiotic, a decrease in systemic inflammation, 
an improvement in cognitive function, and a decrease 
in the recurrence rate of hepatic encephalopathy have 
been reported.(1,16)
In the setting of the proinflammatory state, patients 
with cirrhosis present alterations in the neutrophil 
Fig. 4. Parameters of intestinal barrier and bacterial translocation at baseline and at the end of treatment (12 weeks) in the placebo 
group and in the probiotic group: FABP-6 (A), FABP-2 (B), zonulin (C), urinary claudin-3 (D), and LBP (E). Data expressed as mean 
± SEM. Higher values indicate more impaired intestinal barrier. P is not significant for any parameters in the placebo group and for 
FABP-2, zonulin, and LBP (P = 0.13) in the probiotic group.
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oxidative burst that can contribute to worsening prog-
nosis and increase the risk of bacterial infections.(34,35) 
Among these alterations, the impaired production of 
reactive oxygen species after stimulation is especially 
relevant.(35) This exhaustion of neutrophils is consid-
ered to be mainly due to the maintained proinflam-
matory state in the setting of repeated translocation 
of intestinal bacteria or their products (i.e,. endo-
toxin) as a consequence of the impaired intestinal bar-
rier.(35) In our study, patients receiving the probiotic 
showed an improvement in neutrophil oxidative burst 
after stimulation. This finding is probably related to 
the decrease in the proinflammatory state and may 
help prevent infections and improve prognosis in 
these patients.(34,35) Interestingly, Stadlbauer et al.(36) 
observed that treatment with a single species probiotic 
(Lactobacillus casei Shirota) restored neutrophil phago-
cytic capacity in patients with compensated alcoholic 
cirrhosis. This effect was probably a consequence of 
an improvement in pathological bacterial transloca-
tion, as suggested by the decrease in the neutrophil 
toll-like receptor 4 expression after stimulation with 
endotoxin in patients treated with the probiotic.(36) In 
a more recent study, Horvath et al.(37) reported that 
treatment with a different multispecies probiotic in 
outpatients with cirrhosis produced an immune mod-
ulation consisting of an increase in neutrophil resting 
oxidative burst and serum neopterin, a marker of mac-
rophage activation.
Because probiotics can improve the intestinal bar-
rier, we assessed several biomarkers of gut barrier 
integrity. We observed a decrease in serum FABP-6 
and urinary claudin-3 in the probiotic group at the 
end of treatment, suggesting a possible improvement 
in the intestinal barrier,(23) without significant changes 
in serum FABP-2 and zonulin. Interestingly, FABP-2 
is considered to reflect the intestinal barrier in the 
whole gut, whereas FABP-6 is more specific of the 
ileum.(23) Therefore, our findings suggest a more spe-
cific effect of the probiotic in this area. Previous stud-
ies have demonstrated a beneficial effect of certain 
probiotics on the intestinal barrier in several experi-
mental and clinical settings.(38,39) This finding has also 
been reported in models of experimental cirrhosis, in 
which several probiotics improved the intestinal bar-
rier, decreased bacterial translocation, and ameliorated 
the proinflammatory state.(40,41) However, in the study 
by Horvath et al.(37) in patients with cirrhosis treated 
with a different probiotic mixture, the authors did not 
observe any significant effect on gut permeability, as 
assessed by a panel of markers including lactulose/
mannitol ratio and fecal zonulin, or inflammatory 
biomarkers. Liu et al.(42) evaluated patients under-
going colorectal surgery treated with a three-strain 
probiotic and reported a decrease in serum zonulin, 
a parameter that was unchanged in our study. These 
discrepancies between studies may be explained by the 
differences in study populations, the probiotic product 
used,(13,14,39) and the assessment parameters. It should 
be pointed out that the biomarkers we used to eval-
uate the intestinal barrier have not been validated in 
cirrhosis. Although previous data in other settings, 
such as intestinal ischemia, intense exercise, human 
immunodeficiency virus infection or chronic hepatitis, 
suggest they could be surrogate parameters to assess 
the integrity of the intestinal barrier,(23,43-45) studies in 
patients with cirrhosis are largely lacking.
Regarding bacterial translocation, we quantified 
LBP in blood and failed to demonstrate signifi-
cant changes after probiotic treatment. However, we 
should again emphasize that the patients were in a 
stable situation and showed relatively well-preserved 
liver function. Therefore, patients presented low levels 
of LBP at baseline, suggesting a low degree of bacte-
rial translocation that would be difficult to improve 
with any treatment. We cannot rule out the possibility 
that the probiotic treatment produced a decrease in 
bacterial translocation of enterobacteria, suggested by 
the slight decrease in LBP. This hypothesis should be 
confirmed by sequencing analysis of the composition 
of blood bacterial DNA.(46) Such analysis was not 
conceptualized and therefore not performed in the 
present study. Using a different probiotic, Lactobacillus 
GG, Bajaj et al.(15) found that endotoxemia and 
serum TNF-α decreased and fecal microbiota dysbi-
osis improved in patients with cirrhosis with minimal 
hepatic encephalopathy.
We studied the fecal microbiota by 16S ribosomal 
DNA sequencing in a subgroup of patients and failed 
to demonstrate significant changes at the end of 
the treatment in either group. This finding must be 
considered with caution due to the small number of 
patients studied (9 in the probiotic group and 8 in the 
placebo group) and the potential confounding factors, 
such as inadvertent changes in life style. Moreover, 
the analysis of the fecal microbiota does not neces-
sarily reflect changes in upper areas of the gut, where 
these changes could have more physiopathological 
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consequences in the setting of cirrhosis.(47) Another 
possible explanation is that the probiotic treatment 
did not produce a change in the microbiota compo-
sition but in its functions, as has been reported with 
rifaximin(48) and with the same probiotic as that used 
here in other settings.(49)
Adverse events were similar in the two groups, 
and no side effects attributable to the probiotic were 
observed, confirming previous studies and suggesting 
that this probiotic is safe in this setting.(16,27)
We hypothesize that the probiotic ameliorated 
the intestinal barrier and modulated the crosstalk 
between intestinal bacteria and the immune system. 
As a consequence, there was a decrease in systemic 
inflammation, and probably in neuroinflammation 
(not evaluated in the present study), and therefore an 
improvement in cognition and neural circuits involved 
in gait, which finally would decrease the risk of falls. 
The correlations between the parameters of the intes-
tinal barrier, the inflammatory response, cognitive 
function, and the risk of falling observed in the pres-
ent study further support this hypothesis.
Our study has several limitations. The first of these 
is related to the fact that to obtain more robust con-
clusions about the effects of the probiotic, we applied 
strict exclusion criteria to control for potential con-
founding factors. However, this resulted in a study 
population with a relatively well-preserved liver func-
tion and a small sample size, as we were able to include 
only 36 patients over a 3-year period. Consequently, 
it was difficult to show an improvement in several 
mildly impaired parameters, and the high number of 
patients excluded limited the potential applicability of 
the study results to a broader group of patients with 
cirrhosis in clinical practice.
A second limitation is that the biomarkers used to 
evaluate the gut barrier are not validated in cirrho-
sis. We preferred not to use other more standardized 
methods, such as the administration of lactulose/man-
nitol or polyethylene glycol,(23) because they included 
the administration of medications that were not per-
mitted in accordance with the study design. Lactulose 
and polyethylene glycol are used to treat hepatic 
encephalopathy and could interfere with the param-
eters we aimed to evaluate, such as intestinal micro-
biota or cognitive function,(27,50) and therefore many 
of the other related parameters, such as inflammatory 
response or risk of falls. Nevertheless, we would like to 
point out that the results from the biomarkers used in 
the present study that could suggest an improvement 
in the intestinal barrier after probiotic treatment are 
consistent with previous data.(23,38-45)
As future research, a study with a larger number 
of patients and with a longer treatment protocol is 
warranted to assess the usefulness of the probiotic in 
decreasing the incidence of falls. Moreover, it would 
be interesting to analyze the intimate mechanisms 
determining the improvement in the risk for falls 
through accurate neurological tests and MRI-based 
techniques(30,31) as well as the changes in the microbi-
ota function after probiotic treatment.(48,49)
We conclude that this multistrain probiotic 
improved cognitive function, decreased the risk of falls, 
and modulated the systemic inflammatory response in 
patients with cirrhosis and cognitive dysfunction and/
or previous falls. This probiotic mixture could be use-
ful in the prevention of falls and complications, espe-
cially hepatic encephalopathy and bacterial infections, 
in patients with cirrhosis.
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